Impact BioMedical Approves 1-for-12.62 Reverse Stock Split to Facilitate Merger

Key Facts

1Impact BioMedical's Board of Directors approved a 1-for-12.62 reverse stock split of its common stock.

2The reverse split will become effective on September 23, 2026, with shares continuing to trade under the ticker IBO.

In a move reflecting corporate restructuring to meet merger requirements, Impact BioMedical announced that its Board of Directors has approved a 1-for-12.62 reverse stock split of its common stock. According to reports, the split is scheduled to become effective on September 23, 2026, with shares continuing to trade under the ticker symbol IBO. This action is primarily intended to facilitate the completion of the company's planned merger with Zoar Ltd. (formerly known as Dr. Ashley's Ltd.).

This corporate action comes as the company seeks to strengthen its capital structure and ensure compliance with continued exchange listing standards. Under the terms of the split, every 12.62 shares of issued and outstanding common stock will be combined into one new share, significantly reducing the total share count. This consolidation is a critical step in supporting the business combination with Zoar Ltd, where Impact stockholders are expected to receive shares in the combined entity upon closing.

Regarding market performance, IBO shares stood at $0.441 at the close of September 10, 2026, having traded between a day low of $0.4337 and a high of $0.5082 per market data. Traders will be watching for the impact of this consolidation on share liquidity and market value when it takes effect later this month, while the upcoming economic calendar shows no immediate sector-specific catalysts in the next few days.